N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
New Approaches to Neuroblastoma Therapy Consortium
Study ID
NCT00093353
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
1 Year - 30 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as irinotecan and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Temozolomide may help irinotecan kill more tumor cells by making them more sensitive to the drug. Cefixime may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given together with temozolomide and cefixime in treating young patients with recurrent or resistant neuroblastoma.

Key Dates

Start date
May 31, 2004
Status verified
May 2009
Primary completion
Jul 31, 2006

Study Design

Enrollment
30 participants (estimated)
Primary purpose
TREATMENT

Locations (13)

Find similar trials in Los Angeles, CA

By condition

Related Studies